Use of thromboelastography before the administration of hemostatic agents to safely taper recombinant activated factor VII in acquired hemophilia A: a report of three cases

Table 1 Characteristics of 3 patients with acquired hemophilia A that underwent TEG-based analyses

Case number	Age	Sex	Symptoms	Coagulation tests performed at diagnosis				Immunosuppressive	Inhibitor	Outcome
Case number	Age	Sex	Symptoms	PT-INR	APTT (sec)	FVIII:C (%)	FVIII inhibitor (BU)	therapy	recurrence	Outcome
Case 1	82	Female	Bullae with bleeding, Nasal hemorrhage	1.09	80	0.7	5.4	PSL^a	No	Alive at 32 M
Case 2	56	Male	Left shoulder joint pain, Difficulty walking	0.96	68	1.3	3.2	PSL^a, CPA^b, Rituximab	No	Alive at 31 M
Case 3	58	Female	Intramuscular hematoma in left leg, Difficulty walking	0.97	94	1.1	5.9	PSL^a	No	Alive at 18 M

The reference ranges for the PT-INR, APTT, and FVIII:C are 0.8-1.2, 25-35 sec, and 60-140%, respectively
The lower limit of detection of the Bethesda assay was 0.1 BU.
TEG Thromboelastography. PT-INR Prothrombin time-international normalized ratio; APTT Activated partial thromboplastin time
FVIII:C Factor VIII coagulant activity, FVIII Factor VIII, BU Bethesda units, M Months
^aPSL Prednisolone, ^bCPA Cyclophosphamide

ISSN: 1477-9560